Cellectis S.A. (NASDAQ:CLLS - Get Free Report)'s share price passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.03 and traded as high as $3.41. Cellectis shares last traded at $3.24, with a volume of 4,833 shares.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on CLLS. Barclays assumed coverage on Cellectis in a research note on Thursday, May 28th. They set an "overweight" rating and a $9.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Cellectis in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Cellectis presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.
Get Our Latest Stock Analysis on Cellectis
Cellectis Price Performance
The stock has a market cap of $325.10 million, a price-to-earnings ratio of -4.98 and a beta of 2.92. The company has a quick ratio of 1.37, a current ratio of 1.37 and a debt-to-equity ratio of 1.61. The company's 50-day moving average is $3.03 and its 200-day moving average is $3.38.
Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.04. The firm had revenue of $6.90 million for the quarter, compared to analyst estimates of $11.05 million. Cellectis had a negative net margin of 102.34% and a negative return on equity of 94.19%.
Hedge Funds Weigh In On Cellectis
Large investors have recently modified their holdings of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Cellectis by 228.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock valued at $5,856,000 after buying an additional 3,284,409 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Cellectis during the fourth quarter worth $15,385,000. Citadel Advisors LLC acquired a new position in shares of Cellectis during the third quarter valued at $633,000. Marshall Wace LLP boosted its holdings in Cellectis by 1,610.3% in the fourth quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company's stock valued at $864,000 after acquiring an additional 168,038 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in Cellectis by 61.9% in the third quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company's stock valued at $165,000 after acquiring an additional 22,080 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors and hedge funds.
About Cellectis
(
Get Free Report)
Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.
The company's core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
